(secondQuint)Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity.

 This was a Phase I, randomized, placebo-controlled, double-blinded, dose ranging study designed to assess the safety, tolerability, and immunogenicity of C.

 difficile vaccine.

 The study was conducted in healthy male and female adults, 18 to 55 years old.

 Subjects was randomly assigned on Day 0 to receive one of two doses of C.

 difficile vaccine (50 or 100 mcg) or placebo (vehicle control containing alum).

.

 Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity@highlight

This Phase I, randomized, placebo-controlled, double-blinded, dose ranging study to assess the safety, tolerability, and immunogenicity of 2 dose levels of C.

 difficile vaccine.

 Population: healthy male and female adults, 18 to 55 years old.

